Alison L. Drake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alison L. Drake has a total of 263 co-authors. Here are the top co-authors by number of shared publications:
- Grace John-Stewart
Department of Global Health, University of Washington, Seattle, USA
16 shared publications - John Kinuthia
Department of Global Health, University of Washington , Seattle, Washington
13 shared publications John Kinuthia
Department of Research & Programs, Kenyatta National Hospital, Nairobi, Kenya
12 shared publicationsDaniel Matemo
Research and Programmes, Kenyatta National Hospital, Nairobi, Kenya
10 shared publicationsBarbra A. Richardson
Department of Global Health, University of Washington, Seattle, WA, USA and Department of Biostatistics, University of Washington, Seattle, WA USA
8 shared publications- Jennifer Beth Unger
Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA
8 shared publications
Latest Publications
- 4 April 2026
- Published by Springer Nature in Journal of Public Health Policy
- Vol. 47 (2) , 291-301
A review of national guidelines on preventing mother-to-child transmission of HIV, syphilis, and hepatitis B in the African region: testing practices for triple elimination
World Health Organization (WHO) updated guidelines for maternal HIV, syphilis and hepatitis B virus (HBV) testing for pregnant women. We reviewed national
- 4 April 2026
- Published by Springer Nature in Journal of Public Health Policy
- Vol. 47 (2) , 291-301
A review of national guidelines on preventing mother-to-child transmission of HIV, syphilis, and hepatitis B in the African region: testing practices for triple elimination
World Health Organization (WHO) updated guidelines for maternal HIV, syphilis and hepatitis B virus (HBV) testing for pregnant women. We reviewed national
- Open Access
User experiences with a digital health family planning counseling tool for women living with HIV in Kenya
Women with HIV(WLHIV) have diverse and complex reproductive health needs that require patient-centered, informed decision making. Digital tools to support reproductive life planning may improve reproductive health counseling and outcomes for these women. We evaluated user-experiences with a self-administered, tablet-based family planning(FP) counseling tool as part of a packaged digital health intervention evaluated in a cluster randomized trial in Kenya. We conducted focus group discussions with WLWH who received the counseling tool(n=10) and in-depth interviews with providers(n=10). Data were collected using semi-structured guides, transcribed, translated, and thematically analyzed. Among 95 women, median age was 26 years and 52% were married. Providers had median 7 years’ experience. WLWH and providers found the counseling tool acceptable, and felt it improved decision-making, FP knowledge, and patient-provider interactions. Women reported the counseling tool supported informed FP decisions, educated on less familiar options, and dispelled myths and misconceptions. Providers said the counseling tool helped tailor counseling though it was challenging to use with women with more FP experience or with a selected method, but helpful among FP-initiators and adolescents. The counseling tool was useful and acceptable, but too lengthy. Tailoring the counseling tool and making it optional for specific groups of WLWH may improve feasibility.
Open AccessUser experiences with a digital health family planning counseling tool for women living with HIV in Kenya
Women with HIV(WLHIV) have diverse and complex reproductive health needs that require patient-centered, informed decision making. Digital tools to support reproductive life planning may improve reproductive health counseling and outcomes for these women. We evaluated user-experiences with a self-administered, tablet-based family planning(FP) counseling tool as part of a packaged digital health intervention evaluated in a cluster randomized trial in Kenya. We conducted focus group discussions with WLWH who received the counseling tool(n=10) and in-depth interviews with providers(n=10). Data were collected using semi-structured guides, transcribed, translated, and thematically analyzed. Among 95 women, median age was 26 years and 52% were married. Providers had median 7 years’ experience. WLWH and providers found the counseling tool acceptable, and felt it improved decision-making, FP knowledge, and patient-provider interactions. Women reported the counseling tool supported informed FP decisions, educated on less familiar options, and dispelled myths and misconceptions. Providers said the counseling tool helped tailor counseling though it was challenging to use with women with more FP experience or with a selected method, but helpful among FP-initiators and adolescents. The counseling tool was useful and acceptable, but too lengthy. Tailoring the counseling tool and making it optional for specific groups of WLWH may improve feasibility.
- 1 September 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 100 (1) , 6-11
Brief Report:Maternal HIV Retesting During Pregnancy and Postpartum Among High-Risk Populations in Kenya, South Africa, and Ukraine: Cost-Effectiveness of Preventing Vertical Transmission
Introduction: Key populations, including female sex workers (FSW), people who inject drugs (PWID), and people in serodiscordant partnerships, experience higher HIV incidence than the general population. Maternal HIV retesting, particularly during late pregnancy, helps detect new infections and prevent vertical HIV transmission, but optimal testing schedules among key populations are unknown. Methods: We used a Markov model to estimate the health and economic impacts of maternal HIV retesting on vertical HIV transmission outcomes among FSW and PWID in Kenya, South Africa, and prewar Ukraine, and among pregnant people in serodiscordant partnerships in Kenya and South Africa. We calculated incremental cost-effectiveness ratios for 7 maternal retesting scenarios that included HIV testing during early antenatal care (ANC) and retesting from late ANC through 9 months postpartum. Results: Retesting during late ANC was estimated to avert 16% (Kenya), 14% (South Africa), and 8% (Ukraine) of infant HIV infections among key populations. Retesting during late ANC was cost-saving or cost-effective among all populations included in our model in South Africa and Kenya. In Ukraine, HIV retesting during late ANC was cost-saving for PWID but not cost-effective for FSW. Postpartum retesting was not cost-effective in any population. Conclusions: Maternal HIV retesting during late ANC is cost-saving or cost-effective for vertical HIV transmission outcomes for pregnant key populations and serodiscordant couples in Kenya and South Africa and is cost-saving for PWID in Ukraine.
- 1 September 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 100 (1) , 6-11
Brief Report:Maternal HIV Retesting During Pregnancy and Postpartum Among High-Risk Populations in Kenya, South Africa, and Ukraine: Cost-Effectiveness of Preventing Vertical Transmission
Introduction: Key populations, including female sex workers (FSW), people who inject drugs (PWID), and people in serodiscordant partnerships, experience higher HIV incidence than the general population. Maternal HIV retesting, particularly during late pregnancy, helps detect new infections and prevent vertical HIV transmission, but optimal testing schedules among key populations are unknown. Methods: We used a Markov model to estimate the health and economic impacts of maternal HIV retesting on vertical HIV transmission outcomes among FSW and PWID in Kenya, South Africa, and prewar Ukraine, and among pregnant people in serodiscordant partnerships in Kenya and South Africa. We calculated incremental cost-effectiveness ratios for 7 maternal retesting scenarios that included HIV testing during early antenatal care (ANC) and retesting from late ANC through 9 months postpartum. Results: Retesting during late ANC was estimated to avert 16% (Kenya), 14% (South Africa), and 8% (Ukraine) of infant HIV infections among key populations. Retesting during late ANC was cost-saving or cost-effective among all populations included in our model in South Africa and Kenya. In Ukraine, HIV retesting during late ANC was cost-saving for PWID but not cost-effective for FSW. Postpartum retesting was not cost-effective in any population. Conclusions: Maternal HIV retesting during late ANC is cost-saving or cost-effective for vertical HIV transmission outcomes for pregnant key populations and serodiscordant couples in Kenya and South Africa and is cost-saving for PWID in Ukraine.
- Open Access
Alignment of contraceptive method attribute preferences and use among Kenyan women living with HIV
Objective: Understanding alignment of contraceptive preferences and method selection among women living with HIV (WLWH) may improve contraceptive counseling. We examined whether method attribute preferences aligned with method attributes used among WLWH, and identified preference clusters. Study Design: We used baseline data from WLWH enrolled in a cluster randomized controlled trial of a reproductive health counseling intervention in Kenya. Women using modern contraception at baseline were eligible (N=2,599). We used Poisson regression models to characterize 11 relationships between method attributes preferred vs used, and principal component analysis (PCA) to identify preferences clusters. Results: Women who preferred methods that are long-acting (adjusted Prevalence Ratio [aPR]:1.63, 95% Confidence Interval [CI]:1.19-2.24), avoid daily dosing (aPR:1.11, 95% CI:1.07-1.16), permit self-discontinuation (aPR:1.32, 95% CI:1.14-1.52), and are concealable (aPR:1.06, 95% CI:1.01-1.12) were significantly more likely to use aligned methods. Attribute preferences clustered on three dimensions: (1) avoiding heavy bleeding, weight changes, libido changes, and non-hormonal; (2) long-acting, avoiding daily dosing, permitting self-discontinuation, and avoiding intermittent bleeding; and (3) concealability without an effectiveness preference. Immediate return to fertility was modeled independently due to lack of clustering. The first dimension was positively correlated with condom use and inversely with implant use. The second was also positively correlated with condom use, and use of both implants and tubal ligation, while inversely with injectable and oral contraceptive pill use. The third was correlated with injectable use. Conclusion: Method attribute preferences do not always align with methods used and may cluster in ways that cannot be satisfied by existing methods. Implications: Preferences for methods that are long-acting, avoid daily dosing, and permit self-discontinuation are widely held and related to method selection, but cannot be met by a single method when held in combination. Client-centered counseling can elicit relative strength of preferences and tailor guidance accordingly, improving method satisfaction.
Open AccessAlignment of contraceptive method attribute preferences and use among Kenyan women living with HIV
Objective: Understanding alignment of contraceptive preferences and method selection among women living with HIV (WLWH) may improve contraceptive counseling. We examined whether method attribute preferences aligned with method attributes used among WLWH, and identified preference clusters. Study Design: We used baseline data from WLWH enrolled in a cluster randomized controlled trial of a reproductive health counseling intervention in Kenya. Women using modern contraception at baseline were eligible (N=2,599). We used Poisson regression models to characterize 11 relationships between method attributes preferred vs used, and principal component analysis (PCA) to identify preferences clusters. Results: Women who preferred methods that are long-acting (adjusted Prevalence Ratio [aPR]:1.63, 95% Confidence Interval [CI]:1.19-2.24), avoid daily dosing (aPR:1.11, 95% CI:1.07-1.16), permit self-discontinuation (aPR:1.32, 95% CI:1.14-1.52), and are concealable (aPR:1.06, 95% CI:1.01-1.12) were significantly more likely to use aligned methods. Attribute preferences clustered on three dimensions: (1) avoiding heavy bleeding, weight changes, libido changes, and non-hormonal; (2) long-acting, avoiding daily dosing, permitting self-discontinuation, and avoiding intermittent bleeding; and (3) concealability without an effectiveness preference. Immediate return to fertility was modeled independently due to lack of clustering. The first dimension was positively correlated with condom use and inversely with implant use. The second was also positively correlated with condom use, and use of both implants and tubal ligation, while inversely with injectable and oral contraceptive pill use. The third was correlated with injectable use. Conclusion: Method attribute preferences do not always align with methods used and may cluster in ways that cannot be satisfied by existing methods. Implications: Preferences for methods that are long-acting, avoid daily dosing, and permit self-discontinuation are widely held and related to method selection, but cannot be met by a single method when held in combination. Client-centered counseling can elicit relative strength of preferences and tailor guidance accordingly, improving method satisfaction.
- Open Access
Strategies and missed opportunities in achieving triple elimination of mother-to-child transmission (EMTCT) of HIV, syphilis, and hepatitis B virus: a scoping review
Eliminating mother-to-child transmission (EMTCT) of HIV, syphilis, and hepatitis B virus (HBV) is a global public health priority. Despite progress towards reducing rates of mother-to-child transmission (MTCT) of HIV, global progress toward EMTCT of syphilis and HBV remains suboptimal. We systematically searched records in PubMed capturing the synergistic challenges and potential strategies in achieving triple EMTCT between January 1, 2013, and April 27, 2023. After screening 547 records, 50 reports met inclusion criteria. Overall, testing for HIV was well-established within antenatal care but limited for syphilis and HBV due to poor political support, inadequate funding, and insufficient operational guidance on how to deliver integrated testing within maternal and child health care. MTCT of syphilis and HBV appears to be impeded by lack of integrated systems to enable test-and-treat approaches with same-day test results and immediate treatment initiation, gaps in linkage to care, frequent stockouts of essential drugs and other commodities, prohibitive user fees, and limited clinical familiarity and training of staff in managing syphilis and HBV positive cases. To achieve triple EMTCT, co-strategies that leverage success of HIV programs to gain momentum towards prevention of congenital syphilis and MTCT of HBV, that break down siloed programs by co-delivery of testing, treatment, and training and that are supported through political will, advocacy, policy and funding are critical.
Open AccessStrategies and missed opportunities in achieving triple elimination of mother-to-child transmission (EMTCT) of HIV, syphilis, and hepatitis B virus: a scoping review
Eliminating mother-to-child transmission (EMTCT) of HIV, syphilis, and hepatitis B virus (HBV) is a global public health priority. Despite progress towards reducing rates of mother-to-child transmission (MTCT) of HIV, global progress toward EMTCT of syphilis and HBV remains suboptimal. We systematically searched records in PubMed capturing the synergistic challenges and potential strategies in achieving triple EMTCT between January 1, 2013, and April 27, 2023. After screening 547 records, 50 reports met inclusion criteria. Overall, testing for HIV was well-established within antenatal care but limited for syphilis and HBV due to poor political support, inadequate funding, and insufficient operational guidance on how to deliver integrated testing within maternal and child health care. MTCT of syphilis and HBV appears to be impeded by lack of integrated systems to enable test-and-treat approaches with same-day test results and immediate treatment initiation, gaps in linkage to care, frequent stockouts of essential drugs and other commodities, prohibitive user fees, and limited clinical familiarity and training of staff in managing syphilis and HBV positive cases. To achieve triple EMTCT, co-strategies that leverage success of HIV programs to gain momentum towards prevention of congenital syphilis and MTCT of HBV, that break down siloed programs by co-delivery of testing, treatment, and training and that are supported through political will, advocacy, policy and funding are critical.
- Open Access
Maternal HIV retesting during pregnancy and postpartum among high-risk populations in Kenya, South Africa, and Ukraine: Cost-effectiveness of preventing vertical transmission
Introduction Key populations, including female sex workers (FSW), people who inject drugs (PWID), and people in serodiscordant partnerships, experience higher HIV incidence compared to the general population. Maternal HIV retesting, particularly during late pregnancy, helps detect new infections and prevent vertical HIV transmission, but optimal testing schedules among key populations are unknown. Methods We used a Markov model to estimate the health and economic impacts of maternal HIV retesting on vertical HIV transmission outcomes among FSW and PWID in Kenya, South Africa, and pre-war Ukraine as well as among pregnant people in serodiscordant partnerships in Kenya and South Africa. We calculated incremental cost-effectiveness ratios (ICERs) for seven maternal retesting scenarios that included HIV testing during early antenatal care (ANC) and retesting from late ANC through nine months postpartum. Results Retesting during late ANC was estimated to avert 16% (Kenya), 14% (South Africa), and 8% (Ukraine) of infant HIV infections among key populations. Retesting during late ANC was cost-saving or cost-effective among all populations included in our model in South Africa and Kenya. In Ukraine, HIV retesting during late ANC was cost-saving for PWID but not cost-effective for FSW. Postpartum retesting was not cost-effective in any population. Conclusions Maternal HIV retesting during late ANC is cost-saving or cost-effective for vertical HIV transmission outcomes for pregnant key populations and serodiscordant couples in Kenya and South Africa and is cost-saving for PWID in Ukraine. Funding USAID, Bill and Melinda Gates Foundation, and National Institutes of Health
Open AccessMaternal HIV retesting during pregnancy and postpartum among high-risk populations in Kenya, South Africa, and Ukraine: Cost-effectiveness of preventing vertical transmission
Introduction Key populations, including female sex workers (FSW), people who inject drugs (PWID), and people in serodiscordant partnerships, experience higher HIV incidence compared to the general population. Maternal HIV retesting, particularly during late pregnancy, helps detect new infections and prevent vertical HIV transmission, but optimal testing schedules among key populations are unknown. Methods We used a Markov model to estimate the health and economic impacts of maternal HIV retesting on vertical HIV transmission outcomes among FSW and PWID in Kenya, South Africa, and pre-war Ukraine as well as among pregnant people in serodiscordant partnerships in Kenya and South Africa. We calculated incremental cost-effectiveness ratios (ICERs) for seven maternal retesting scenarios that included HIV testing during early antenatal care (ANC) and retesting from late ANC through nine months postpartum. Results Retesting during late ANC was estimated to avert 16% (Kenya), 14% (South Africa), and 8% (Ukraine) of infant HIV infections among key populations. Retesting during late ANC was cost-saving or cost-effective among all populations included in our model in South Africa and Kenya. In Ukraine, HIV retesting during late ANC was cost-saving for PWID but not cost-effective for FSW. Postpartum retesting was not cost-effective in any population. Conclusions Maternal HIV retesting during late ANC is cost-saving or cost-effective for vertical HIV transmission outcomes for pregnant key populations and serodiscordant couples in Kenya and South Africa and is cost-saving for PWID in Ukraine. Funding USAID, Bill and Melinda Gates Foundation, and National Institutes of Health
- Open Access
Are we testing for triple elimination? A review of national guidelines on preventing mother-to-child transmission of HIV, syphilis, and hepatitis B in the African region
Introduction: World Health Organization (WHO) updated guidelines for maternal HIV, syphilis and hepatitis B virus (HBV) testing for pregnant women, and advised on using dual HIV/syphilis rapid diagnostic tests (RDTs). We reviewed national testing guidelines to assess political support in alignment with WHO guidance and triple elimination of mother-to-child transmission (MTCT) priorities. Methods: We reviewed national HIV-related guidelines from 46 African countries after 2010, including guidelines on prevention MTCT, HIV testing/self-testing, HIV antiretroviral treatment, and/or HIV pre-exposure prophylaxis. Data was extracted data on recommendations for maternal testing for HIV (frequency and timing), syphilis (any test/test type); and HBV. Testing recommendations for all three infections in the most recent country guidelines were compared to WHO guidelines. Results: Testing policies on HIV, syphilis, or HBV during pregnancy and/or postpartum from 38 (83%) countries were identified; 18 (47%) had policies updated after 2019 and 11 (29%) were high HIV burden. All 38 countries with HIV testing guidelines addressed maternal HIV retesting, while 68% had guidelines recommending syphilis testing (46% of which recommended the dual RDT), and 58% had HBV testing guidelines. Maternal HIV retesting was more frequent than recommended by WHO in 2019 in 9/11 (82%) and 7/27 (26%) of high and low HIV burden countries, respectively. Half of countries had triple elimination of MTCT focused policies, and 10 (26%) had maternal HIV retesting as well as syphilis and/or HBV testing guidance. Conclusions: Half of countries had guidelines to test for all three infections; policy evaluations to measure implementation and impact are needed.
Open AccessAre we testing for triple elimination? A review of national guidelines on preventing mother-to-child transmission of HIV, syphilis, and hepatitis B in the African region
Introduction: World Health Organization (WHO) updated guidelines for maternal HIV, syphilis and hepatitis B virus (HBV) testing for pregnant women, and advised on using dual HIV/syphilis rapid diagnostic tests (RDTs). We reviewed national testing guidelines to assess political support in alignment with WHO guidance and triple elimination of mother-to-child transmission (MTCT) priorities. Methods: We reviewed national HIV-related guidelines from 46 African countries after 2010, including guidelines on prevention MTCT, HIV testing/self-testing, HIV antiretroviral treatment, and/or HIV pre-exposure prophylaxis. Data was extracted data on recommendations for maternal testing for HIV (frequency and timing), syphilis (any test/test type); and HBV. Testing recommendations for all three infections in the most recent country guidelines were compared to WHO guidelines. Results: Testing policies on HIV, syphilis, or HBV during pregnancy and/or postpartum from 38 (83%) countries were identified; 18 (47%) had policies updated after 2019 and 11 (29%) were high HIV burden. All 38 countries with HIV testing guidelines addressed maternal HIV retesting, while 68% had guidelines recommending syphilis testing (46% of which recommended the dual RDT), and 58% had HBV testing guidelines. Maternal HIV retesting was more frequent than recommended by WHO in 2019 in 9/11 (82%) and 7/27 (26%) of high and low HIV burden countries, respectively. Half of countries had triple elimination of MTCT focused policies, and 10 (26%) had maternal HIV retesting as well as syphilis and/or HBV testing guidance. Conclusions: Half of countries had guidelines to test for all three infections; policy evaluations to measure implementation and impact are needed.
- Open Access
- 13 August 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (8) , e0302077
Preferences and uptake of home-based HIV self-testing for maternal retesting in Kenya
Objective: To compare preferences, uptake, and cofactors for unassisted home-based oral self-testing (HB-HIVST) versus clinic-based rapid diagnostic blood tests (CB-RDT) for maternal HIV retesting. Design: Prospective cohort. Methods: Between November 2017 and June 2019, HIV-negative pregnant Kenyan women receiving antenatal care were enrolled and given a choice to retest with HB-HIVST or CB-RDT. Women were asked to retest between 36 weeks gestation and 1-week post-delivery if the last HIV test was <24 weeks gestation or at 6 weeks postpartum if ≥24 weeks gestation, and self-report on retesting at a 14-week postpartum. Results: Overall, 994 women enrolled and 33% (n = 330) selected HB-HIVST. HB-HIVST was selected because it was private (n = 224, 68%), convenient (n = 211, 63%), and offered flexibility in the timing of retesting (n = 207, 63%), whereas CB-RDT was selected due to the trust of providers to administer the test (n = 510, 77%) and convenience of clinic testing (n = 423, 64%). Among 905 women who reported retesting at follow-up, 135 (15%) used HB-HIVST. Most (n = 595, 94%) who selected CB-RDT retested with this strategy, compared to 39% (n = 120) who selected HB-HIVST retesting with HB-HIVST. HB-HIVST retesting was more common among women with higher household income and those who may have been unable to test during pregnancy (both retested postpartum and delivered <37 weeks gestation) and less common among women who were depressed. Most women said they would retest in the future using the test selected at enrollment (99% [n = 133] HB-HIVST; 93% [n = 715] CB-RDT-RDT). Conclusions: While most women preferred CB-RDT for maternal retesting, HB-HIVST was acceptable and feasible and could be used to expand HIV retesting options.
- 13 August 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (8) , e0302077
Open AccessPreferences and uptake of home-based HIV self-testing for maternal retesting in Kenya
Objective: To compare preferences, uptake, and cofactors for unassisted home-based oral self-testing (HB-HIVST) versus clinic-based rapid diagnostic blood tests (CB-RDT) for maternal HIV retesting. Design: Prospective cohort. Methods: Between November 2017 and June 2019, HIV-negative pregnant Kenyan women receiving antenatal care were enrolled and given a choice to retest with HB-HIVST or CB-RDT. Women were asked to retest between 36 weeks gestation and 1-week post-delivery if the last HIV test was <24 weeks gestation or at 6 weeks postpartum if ≥24 weeks gestation, and self-report on retesting at a 14-week postpartum. Results: Overall, 994 women enrolled and 33% (n = 330) selected HB-HIVST. HB-HIVST was selected because it was private (n = 224, 68%), convenient (n = 211, 63%), and offered flexibility in the timing of retesting (n = 207, 63%), whereas CB-RDT was selected due to the trust of providers to administer the test (n = 510, 77%) and convenience of clinic testing (n = 423, 64%). Among 905 women who reported retesting at follow-up, 135 (15%) used HB-HIVST. Most (n = 595, 94%) who selected CB-RDT retested with this strategy, compared to 39% (n = 120) who selected HB-HIVST retesting with HB-HIVST. HB-HIVST retesting was more common among women with higher household income and those who may have been unable to test during pregnancy (both retested postpartum and delivered <37 weeks gestation) and less common among women who were depressed. Most women said they would retest in the future using the test selected at enrollment (99% [n = 133] HB-HIVST; 93% [n = 715] CB-RDT-RDT). Conclusions: While most women preferred CB-RDT for maternal retesting, HB-HIVST was acceptable and feasible and could be used to expand HIV retesting options.
- Open Access
- 10 July 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (7) , e0306992
Evaluating the performance of a risk assessment score tool to predict HIV acquisition among pregnant and postpartum women in Kenya
Background: Clinical risk score tools require validation in diverse settings and populations before they are widely implemented. We aimed to externally validate an HIV risk assessment tool for predicting HIV acquisition among pregnant and postpartum women. In the context of prevention of mother-to-child transmission programs, risk score tools could be used to prioritize retesting efforts and delivery of pre-exposure prophylaxis (PrEP) to pregnant and postpartum women most at risk for HIV acquisition while minimizing unnecessary perinatal exposure.Methods: Data from women enrolled in a cross-sectional study of programmatic HIV retesting and/or receiving maternal and child health care services at five facilities in Western Kenya were used to validate the predictive ability of a simplified risk score previously developed for pregnant/postpartum women. Incident HIV infections were defined as new HIV diagnoses following confirmed negative or unknown status during pregnancy. Predictive performance was assessed using the area under the receiver operating characteristic curve (AUC) and Brier score.Results: Among 1266 women with 35 incident HIV infections, we found an AUC for predicting HIV acquisition of 0.60 (95% CI, 0.51, 0.69), with a Brier score of 0.27. A risk score >6 was associated with a 2.9-fold increase in the odds of HIV acquisition (95% CI, 1.48, 5.70; p = 0.002) vs scores ≤6. Women with risk scores >6 were 27% (346/1266) of the population but accounted for 52% of HIV acquisitions. Syphilis, age at sexual debut, and unknown partner HIV status were significantly associated with increased risk of HIV in this cohort.Conclusion: The simplified risk score performed moderately at predicting risk of HIV acquisition in this population of pregnant and postpartum women and may be useful to guide PrEP use or counseling.
- 10 July 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (7) , e0306992
Open AccessEvaluating the performance of a risk assessment score tool to predict HIV acquisition among pregnant and postpartum women in Kenya
Background: Clinical risk score tools require validation in diverse settings and populations before they are widely implemented. We aimed to externally validate an HIV risk assessment tool for predicting HIV acquisition among pregnant and postpartum women. In the context of prevention of mother-to-child transmission programs, risk score tools could be used to prioritize retesting efforts and delivery of pre-exposure prophylaxis (PrEP) to pregnant and postpartum women most at risk for HIV acquisition while minimizing unnecessary perinatal exposure.Methods: Data from women enrolled in a cross-sectional study of programmatic HIV retesting and/or receiving maternal and child health care services at five facilities in Western Kenya were used to validate the predictive ability of a simplified risk score previously developed for pregnant/postpartum women. Incident HIV infections were defined as new HIV diagnoses following confirmed negative or unknown status during pregnancy. Predictive performance was assessed using the area under the receiver operating characteristic curve (AUC) and Brier score.Results: Among 1266 women with 35 incident HIV infections, we found an AUC for predicting HIV acquisition of 0.60 (95% CI, 0.51, 0.69), with a Brier score of 0.27. A risk score >6 was associated with a 2.9-fold increase in the odds of HIV acquisition (95% CI, 1.48, 5.70; p = 0.002) vs scores ≤6. Women with risk scores >6 were 27% (346/1266) of the population but accounted for 52% of HIV acquisitions. Syphilis, age at sexual debut, and unknown partner HIV status were significantly associated with increased risk of HIV in this cohort.Conclusion: The simplified risk score performed moderately at predicting risk of HIV acquisition in this population of pregnant and postpartum women and may be useful to guide PrEP use or counseling.
- Open Access
- 1 April 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (4) , e0300642
Mobile solutions to Empower reproductive life planning for women living with HIV in Kenya (MWACh EMPOWER): Protocol for a cluster randomized controlled trial
Background: Women living with HIV (WLWH) face unique reproductive health (RH) barriers which increase their risks of unmet need for contraception, contraceptive failure, unintended pregnancy, and pregnancy-related morbidity and mortality and may prevent them from achieving their reproductive goals. Patient-centered counseling interventions that support health care workers (HCWs) in providing high-quality RH counseling, tailored to the needs of WLWH, may improve reproductive health outcomes. Methods and design: We are conducting a non-blinded cluster randomized controlled trial (cRCT) of a digital health intervention for WLWH (clinicaltrials.gov #NCT05285670). We will enroll 3,300 WLWH seeking care in 10 HIV care and treatment centers in Nairobi and Western Kenya. WLWH at intervention sites receive the Mobile WACh Empower intervention, a tablet-based RH decision-support counseling tool administered at baseline and SMS support during two years of follow-up. WLWH at control sites receive the standard of care FP counseling. The decision-support tool is a logic-based tool for family planning (FP) counseling that uses branching logic to guide RH questions based on participants’ reproductive life plans, tailoring counseling based on the responses. Follow-up SMSs are based in the Information-Motivation-Behavioral (IMB) Skills model of behavioral change and are tailored to participant characteristics and reproductive needs through separate SMS “tracks”. Follow-up visits are scheduled quarterly for 2 years to assess plans for pregnancy, pregnancy prevention, and contraceptive use. The primary outcome, FP discontinuation, will be compared using an intent-to-treat analysis. We will also assess the unmet need for FP, dual method use, viral load suppression at conception and unintended pregnancy. Discussion: The Mobile WACh Empower intervention is innovative as it combines a patient-centered counseling tool to support initial reproductive life decisions with longitudinal SMS for continued RH support and may help provide RH care within the context of provision of HIV care.
- 1 April 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (4) , e0300642
Open AccessMobile solutions to Empower reproductive life planning for women living with HIV in Kenya (MWACh EMPOWER): Protocol for a cluster randomized controlled trial
Background: Women living with HIV (WLWH) face unique reproductive health (RH) barriers which increase their risks of unmet need for contraception, contraceptive failure, unintended pregnancy, and pregnancy-related morbidity and mortality and may prevent them from achieving their reproductive goals. Patient-centered counseling interventions that support health care workers (HCWs) in providing high-quality RH counseling, tailored to the needs of WLWH, may improve reproductive health outcomes. Methods and design: We are conducting a non-blinded cluster randomized controlled trial (cRCT) of a digital health intervention for WLWH (clinicaltrials.gov #NCT05285670). We will enroll 3,300 WLWH seeking care in 10 HIV care and treatment centers in Nairobi and Western Kenya. WLWH at intervention sites receive the Mobile WACh Empower intervention, a tablet-based RH decision-support counseling tool administered at baseline and SMS support during two years of follow-up. WLWH at control sites receive the standard of care FP counseling. The decision-support tool is a logic-based tool for family planning (FP) counseling that uses branching logic to guide RH questions based on participants’ reproductive life plans, tailoring counseling based on the responses. Follow-up SMSs are based in the Information-Motivation-Behavioral (IMB) Skills model of behavioral change and are tailored to participant characteristics and reproductive needs through separate SMS “tracks”. Follow-up visits are scheduled quarterly for 2 years to assess plans for pregnancy, pregnancy prevention, and contraceptive use. The primary outcome, FP discontinuation, will be compared using an intent-to-treat analysis. We will also assess the unmet need for FP, dual method use, viral load suppression at conception and unintended pregnancy. Discussion: The Mobile WACh Empower intervention is innovative as it combines a patient-centered counseling tool to support initial reproductive life decisions with longitudinal SMS for continued RH support and may help provide RH care within the context of provision of HIV care.